Evidence of a Novel Mechanism for Partial γ-Secretase Inhibition Induced Paradoxical Increase in Secreted Amyloid β Protein
暂无分享,去创建一个
N. Greig | V. Ramakrishnan | C. Eckman | Z. Ablonczy | C. Crosson | M. Pappolla | K. Sambamurti | V. Padmaraju | E. Eckman | J. Pacheco-Quinto | E. Barnwell | R. Baranello
[1] J. Hardy,et al. A paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of β-amyloid production. , 2013, Cell reports.
[2] M. Wolfe. Toward the structure of presenilin/γ-secretase and presenilin homologs. , 2013, Biochimica et biophysica acta.
[3] Gregory W. Kauffman,et al. Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012 , 2013, Expert opinion on therapeutic patents.
[4] K. Zahs,et al. β-Amyloid oligomers in aging and Alzheimer’s disease , 2013, Front. Aging Neurosci..
[5] J. Ghiso,et al. Major carboxyl terminal fragments generated by γ-secretase processing of the Alzheimer amyloid precursor are 50 and 51 amino acids long. , 2013, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[6] A. Attie,et al. Protein Sorting Motifs in the Cytoplasmic Tail of SorCS1 Control Generation of Alzheimer's Amyloid-β Peptide , 2013, The Journal of Neuroscience.
[7] V. Šendula-Jengić,et al. Modulators of γ-Secretase Activity Can Facilitate the Toxic Side-Effects and Pathogenesis of Alzheimer's Disease , 2013, PloS one.
[8] S. Visser,et al. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data , 2013, European Journal of Clinical Pharmacology.
[9] E. Eckman,et al. Endothelin-converting Enzymes Degrade Intracellular β-Amyloid Produced within the Endosomal/Lysosomal Pathway and Autophagosomes* , 2013, The Journal of Biological Chemistry.
[10] S. Gandy,et al. Dynamin 1 Regulates Amyloid Generation through Modulation of BACE-1 , 2012, PloS one.
[11] A. Georgakopoulos,et al. Cellular mechanisms of γ-secretase substrate selection, processing and toxicity , 2012, Progress in Neurobiology.
[12] Yong Shen,et al. Depletion of GGA1 and GGA3 Mediates Postinjury Elevation of BACE1 , 2012, The Journal of Neuroscience.
[13] A. Levey,et al. GGA1-mediated endocytic traffic of LR11/SorLA alters APP intracellular distribution and amyloid-β production , 2012, Molecular biology of the cell.
[14] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[15] B. Ghetti,et al. The Psen1‐L166P‐knock‐in mutation leads to amyloid deposition in human wild‐type amyloid precursor protein YAC transgenic mice , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] R. Schekman,et al. Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid β (Aβ) production in the trans-Golgi network , 2012, Proceedings of the National Academy of Sciences.
[17] Marc Cruts,et al. Locus-Specific Mutation Databases for Neurodegenerative Brain Diseases , 2012, Human mutation.
[18] B. de Strooper,et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.
[19] J. Hardy,et al. Twenty years of Alzheimer’s disease‐causing mutations , 2012, Journal of neurochemistry.
[20] Bryan Maloney,et al. Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. , 2011, Gene.
[21] Bryan Maloney,et al. The Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motif. , 2011, Gene.
[22] M. Boulton,et al. PEDF Regulates Vascular Permeability by a γ-Secretase-Mediated Pathway , 2011, PloS one.
[23] A. Georgakopoulos,et al. Inhibitors of γ‐secretase stabilize the complex and differentially affect processing of amyloid precursor protein and other substrates , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[24] Carol D. Hicks,et al. Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014. , 2011, Bioorganic & medicinal chemistry letters.
[25] N. Greig,et al. Targets for AD treatment: conflicting messages from γ‐secretase inhibitors , 2011, Journal of neurochemistry.
[26] D. Selkoe,et al. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.
[27] N. Robakis. Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives , 2011, Neurobiology of Aging.
[28] R. J. Kelleher,et al. γ-Secretase and Human Disease , 2010, Science.
[29] J. Cummings. What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease? , 2010, Biological Psychiatry.
[30] J. Wiltfang,et al. Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated , 2010, Molecular Neurodegeneration.
[31] W. Klein,et al. ADDLs and the signaling web that leads to Alzheimer’s disease , 2010, Neuropharmacology.
[32] T. Kudo,et al. The production ratios of AICDε51 and Aβ42 by intramembrane proteolysis of βAPP do not always change in parallel , 2010, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.
[33] N. Robakis. Are Aβ and Its Derivatives Causative Agents or Innocent Bystanders in AD? , 2010, Neurodegenerative Diseases.
[34] Z. Ablonczy,et al. Pigment Epithelium-derived Factor Maintains Retinal Pigment Epithelium Function by Inhibiting Vascular Endothelial Growth Factor-R2 Signaling through γ-Secretase* , 2009, The Journal of Biological Chemistry.
[35] Michael G. Yang,et al. The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression* , 2008, Journal of Biological Chemistry.
[36] S. Paul,et al. Geranylgeranyl pyrophosphate stimulates γ‐secretase to increase the generation of Aβ and APP‐CTFγ , 2008 .
[37] E. Kremmer,et al. Pathological activity of familial Alzheimer’s disease-associated mutant presenilin can be executed by six different γ-secretase complexes , 2007, Neurobiology of Disease.
[38] N. Greig,et al. Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factors. , 2006, Current Alzheimer research.
[39] Tracy M. Brown,et al. Concentration-Dependent Modulation of Amyloid-β in Vivo and in Vitro Using the γ-Secretase Inhibitor, LY-450139 , 2006, Journal of Pharmacology and Experimental Therapeutics.
[40] C. Eckman,et al. Regulation of Steady-state β-Amyloid Levels in the Brain by Neprilysin and Endothelin-converting Enzyme but Not Angiotensin-converting Enzyme* , 2006, Journal of Biological Chemistry.
[41] M. Takeda,et al. A novel alternative splice variant of nicastrin and its implication in Alzheimer disease. , 2006, Life sciences.
[42] N. Greig,et al. A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. , 2006, Current Alzheimer research.
[43] C. Mathers,et al. Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.
[44] J. Hardy,et al. Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration. , 2005, Biochemical Society transactions.
[45] G. Forloni,et al. Rat nicastrin gene: cDNA isolation, mRNA variants and expression pattern analysis. , 2005, Brain research. Molecular brain research.
[46] Bryan Maloney,et al. Functional characterization of the 5′ flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[47] Bryan Maloney,et al. Gene structure and organization of the human β‐secretase (BACE) promoter , 2004 .
[48] M. Seaman. Cargo-selective endosomal sorting for retrieval to the Golgi requires retromer , 2004, The Journal of cell biology.
[49] D. Selkoe,et al. Inhibition of Receptor-mediated Endocytosis Demonstrates Generation of Amyloid β-Protein at the Cell Surface* , 2003, Journal of Biological Chemistry.
[50] J. Hardy,et al. APH1, PEN2, and Nicastrin increase Aβ levels and γ-secretase activity , 2003 .
[51] L. Marlow,et al. Alzheimer's Disease β-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme* , 2003, The Journal of Biological Chemistry.
[52] C. Haass,et al. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts , 2003, The Journal of cell biology.
[53] P. S. St George-Hyslop,et al. Presenilin 1 Mutations Activate γ42-Secretase but Reciprocally Inhibit ε-Secretase Cleavage of Amyloid Precursor Protein (APP) and S3-Cleavage of Notch* , 2002, The Journal of Biological Chemistry.
[54] Wanpin Chang,et al. Memapsin 2 (β‐secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2 , 2002, FEBS letters.
[55] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[56] M. Yanagisawa,et al. Distinct cellular localization and regulation of endothelin-1 and endothelin-converting enzyme-1 expression in the bovine corpus luteum: implications for luteolysis. , 2001, Endocrinology.
[57] L. Onstead,et al. Convertases other than furin cleave β‐secretase to its mature form , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] C. Eckman,et al. Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.
[59] S. Younkin,et al. Presenilins as therapeutic targets for the treatment of Alzheimer's disease. , 2001, Trends in molecular medicine.
[60] M. Tohyama,et al. Absence of endoproteolysis but no effects on amyloid beta production by alternative splicing forms of presenilin-1, which lack exon 8 and replace D257A. , 2000, Brain research. Molecular brain research.
[61] R. Rozmahel,et al. Carboxyl-terminal Fragments of Alzheimer β-Amyloid Precursor Protein Accumulate in Restricted and Unpredicted Intracellular Compartments in Presenilin 1-deficient Cells* , 2000, The Journal of Biological Chemistry.
[62] F. D. Miller,et al. Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.
[63] R. Hammer,et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. , 2000, The Journal of clinical investigation.
[64] C. Haass,et al. Presenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch , 2000, Nature Cell Biology.
[65] J. Hardy,et al. Antisense‐Induced Reduction of Presenilin 1 Expression Selectively Increases the Production of Amyloid β42 in Transfected Cells , 1999, Journal of neurochemistry.
[66] S. Younkin,et al. Glycosylphosphatidylinositol-anchored Proteins Play an Important Role in the Biogenesis of the Alzheimer’s Amyloid β-Protein* , 1999, The Journal of Biological Chemistry.
[67] S. Younkin. The role of Aβ42 in Alzheimer's disease , 1998, Journal of Physiology-Paris.
[68] D. Selkoe,et al. The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐Protein a , 1996 .
[69] D. Selkoe,et al. The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.
[70] N. Robakis,et al. Evidence that secretase cleavage of cell surface Alzheimer amyloid precursor occurs after normal endocytic internalization , 1995, Journal of neuroscience research.
[71] J. Shioi,et al. The Alzheimer's Amyloid Precursor Is Cleaved Intracellularly in the Trans‐Golgi Network or in a Post‐Golgi Compartment a , 1992, Annals of the New York Academy of Sciences.
[72] J. Shioi,et al. Evidence for intracellular cleavage of the Alzheimer's amyloid precursor in PC12 cells , 1992, Journal of neuroscience research.
[73] L. Villa-komaroff,et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. , 1989, Science.
[74] N. Robakis,et al. CHROMOSOME 21q21 SUBLOCALISATION OF GENE ENCODING BETA-AMYLOID PEPTIDE IN CEREBRAL VESSELS AND NEURITIC (SENILE) PLAQUES OF PEOPLE WITH ALZHEIMER DISEASE AND DOWN SYNDROME , 1987, The Lancet.
[75] W. Xia,et al. γ-Secretase modulator in Alzheimer's disease: shifting the end. , 2012, Journal of Alzheimer's disease : JAD.
[76] B. de Strooper,et al. Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. , 2012, Cold Spring Harbor perspectives in medicine.
[77] N. Greig,et al. Differential accumulation of secreted AbetaPP metabolites in ocular fluids. , 2010, Journal of Alzheimer's disease : JAD.
[78] Xuemin Xu. Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. , 2009, Journal of Alzheimer's disease : JAD.
[79] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[80] S. Paul,et al. Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma. , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[81] Tracy M. Brown,et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. , 2006, The Journal of pharmacology and experimental therapeutics.
[82] Bryan Maloney,et al. Gene structure and organization of the human beta-secretase (BACE) promoter. , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[83] L. Refolo,et al. Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization. , 2004, Journal of molecular neuroscience : MN.
[84] J. Hardy,et al. APH1, PEN2, and Nicastrin increase Abeta levels and gamma-secretase activity. , 2003, Biochemical and biophysical research communications.
[85] S. Younkin. The role of A beta 42 in Alzheimer's disease. , 1998, Journal of physiology, Paris.
[86] D. Selkoe,et al. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. , 1996, Annals of the New York Academy of Sciences.